SSL International ousts CEO (chief executive officer) after second profit warning
This article was originally published in Clinica
SSL International has "invited" its CEO to step down in the wake of the company's second profits warning in four months. Speculation about developments at the company had already been heightened following reported disagreements between directors last week and the first of the two profit warnings last November (see Clinica No 946, p 14). Separately, the UK company is also to lose its chairman, Stuart Wallis, who has said he will not renew his contract, which expires at the end of July.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.